Christopher J. Kirk - 11 May 2026 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Reporting relationship: CEO, Director
Issuer ticker: KZR
Reported as of: 11 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 May 2026, 16:30:29 UTC
Prior SEC filing: 13 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Marc Belsky, Attorney-in-Fact

Key filing fact

Christopher J. Kirk filed Form 4 for Kezar Life Sciences, Inc. (KZR) on 11 May 2026.

Key facts

This page summarizes Christopher J. Kirk's Form 4 filing for Kezar Life Sciences, Inc. (KZR).
12 reported transactions and 11 derivative rows are listed below.
Accepted by SEC: 11 May 2026, 16:30.

Change

Previous filing in this sequence was filed on 13 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001744253 Primary reporting owner

Kirk Christopher J.

Relationship: CEO, Director
Address: C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO
Signature: /s/ Marc Belsky, Attorney-in-Fact
Signature date: 11 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KZR transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -43,134
Change %: -100%
Price
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -4,448
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,448
Exercise price: $14.10
Footnotes: F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -17,792
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,792
Exercise price: $23.70
Footnotes: F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -8,896
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,896
Exercise price: $23.70
Footnotes: F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -7,117
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,117
Exercise price: $59.10
Footnotes: F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -87,499
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 87,499
Exercise price: $8.40
Footnotes: F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -120,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 120,000
Exercise price: $6.58
Footnotes: F4

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -8,749
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,749
Exercise price: $22.80
Footnotes: F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -12,499
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,499
Exercise price: $22.80
Footnotes: F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -25,999
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,999
Exercise price: $22.80
Footnotes: F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -16,999
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,999
Exercise price: $22.80
Footnotes: F3

KZR transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -18,999
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,999
Exercise price: $22.80
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Christopher J. Kirk is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct wholly owned subsidiary, Aurinia Merger Sub, Inc., ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the right to receive certain payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement")

Footnote F2

(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR Agreement with Broadridge Corporate Issuer Solutions, LLC, as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

Footnote F3

Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash Amount (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist at the Effective Time, and no consideration was delivered in exchange for such Out-of-the-Money Option.

Footnote F4

Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.